Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Resistance to Pyrrolobenzodiazepine Dimers Is Associated with SLFN11 Downregulation and Can Be Reversed through Inhibition of ATR

1 Mar 2021

Abstract excerpt

Resistance to antibody-drug conjugates (ADCs) has been observed in both preclinical models and clinical studies. However, mechanisms of resistance to pyrrolobenzodiazepine (PBD)-conjugated ADCs have not been well characterized and thus, this study was designed to investigate development of resistance to PBD dimer warheads and PBD-conjugated ADCs. We established a PBD-resistant cell line, 361-PBDr, by treating...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer therapeutics and mechanisms
Share to Neuroblastoma Research and Treatments
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33653945
DOI: 10.1158/1535-7163.mct-20-0351

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Resistance to Pyrrolobenzodiazepine Dimers Is Associated with SLFN11 Downregulation and Can Be Reversed through Inhibition of ATRPMID 33653945Read ↗

SLFN11 is a general target for enhancing the sensitivity of cancer to chemotherapy (DNA-damaging agents)Semantic proximity Read ↗

SLFN11 promotes CDT1 degradation by CUL4 in response to replicative DNA damage, while its absence leads to synthetic lethality with ATR/CHK1 inhibitorsSemantic proximity Read ↗

Exploring Resistance to ETS Targeting Agents in Diffuse Large B-Cell LymphomaSemantic proximity Read ↗

Exploring Resistance to ETS Targeting Agents in Diffuse Large B-Cell Lymphoma.Semantic proximity Read ↗

The DNA repair pathway as a therapeutic target to synergize with trastuzumab deruxtecan in HER2-targeted antibody-drug conjugate–resistant HER2-overexpressing breast cancerSemantic proximity Read ↗

Patritumab deruxtecan induces immunogenic cell deathSemantic proximity Read ↗

Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agentsSemantic proximity Read ↗

PARP1 catalytic domain mutations drive high-level resistance to saruparib while preserving DNA damage response vulnerabilitiesSemantic proximity Read ↗

Histone Deacetylase Inhibitors: Emerging Mechanisms of ResistanceSemantic proximity Read ↗

Schlafen 11 (SLFN11) Kills Cancer Cells Undergoing Unscheduled Re-replicationSemantic proximity Read ↗

Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugsSemantic proximity Read ↗

Targeting Topoisomerase I in the Era of Precision MedicineSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.